drugset / Trial / NCT06416410
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
RandomizedParallel-groupOpen-labelTreatment
Summary
This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2024-08-07
- Primary completion
- 2026-09-30
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Subject | Glecirasib | Small molecule | — | Oral |
| Subject | JAB-3312 | Unknown | — | Oral |
| Comparator | Pemetrexed | Small molecule | — | Intravenous |
| Comparator | Tislelizumab | Monoclonal antibody | — | Intravenous |